These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 8535313

  • 1. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C.
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A, Bordigoni P, Witz F, Bene MC, Schmitt C, Lacour B, Sommelet D.
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

  • 4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 5. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 6. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Rajantie J, Nikoskelainen J, Keiding N.
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [Abstract] [Full Text] [Related]

  • 7. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 8. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 9. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JM.
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA, Saez RA, Selby GB, Confer DL.
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [Abstract] [Full Text] [Related]

  • 11. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, Miyamoto T, Okamura T, Hayashi S, Eto T, Osaki K, Yamasaki K, Shibuya T, Harada N, Teshima T, Matsuishi E, Minematsu T, Minamishima Y, Harada M, Niho Y.
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [Abstract] [Full Text] [Related]

  • 12. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors.
    Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF.
    Clin Infect Dis; 2002 Sep 15; 35(6):703-12. PubMed ID: 12203168
    [Abstract] [Full Text] [Related]

  • 13. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 15; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 14. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA.
    Bone Marrow Transplant; 1997 May 15; 19(10):1001-9. PubMed ID: 9169644
    [Abstract] [Full Text] [Related]

  • 15. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 15; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, Klingebiel T, Dietz K, Löffler J, Bokemeyer C, Müller CA, Kanz L.
    Bone Marrow Transplant; 2000 Apr 15; 25(7):757-63. PubMed ID: 10745262
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
    Maltezou H, Whimbey E, Abi-Said D, Przepiorka D, Champlin R, Goodrich J.
    Bone Marrow Transplant; 1999 Sep 15; 24(6):665-9. PubMed ID: 10490734
    [Abstract] [Full Text] [Related]

  • 18. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J.
    Transplantation; 1995 Dec 15; 60(11):1225-30. PubMed ID: 8525515
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
    Hägglund H, Boström L, Remberger M, Ljungman P, Nilsson B, Ringdén O.
    Bone Marrow Transplant; 1995 Dec 15; 16(6):747-53. PubMed ID: 8750264
    [Abstract] [Full Text] [Related]

  • 20. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T, Morishima Y, Kitaori K, Kato C, Sao H.
    Int J Hematol; 1999 Aug 15; 70(2):119-26. PubMed ID: 10497851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.